Thromb Haemost 2016; 116(06): 1172-1179
DOI: 10.1160/TH16-04-0335
Stroke, Systemic or Venous Thromboembolism
Schattauer Publishers Schattauer

Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE)

Rationale and design
Jeffrey I. Weitz
1  McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
,
Sylvia Haas
2  Formerly: Technical University of Munich, Munich, Germany
,
Walter Ageno
3  University of Insubria, Varese, Italy
,
Pantep Angchaisuksiri
4  Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Henri Bounameaux
5  Division of Angiology and Hemostasis, University Hospitals of Geneva, Switzerland
,
Joern Dalsgaard Nielsen
6  Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark
,
Samuel Z. Goldhaber
7  Harvard Medical School, Boston, Massachusetts, USA
,
Shinya Goto
8  Tokai University, Kanagawa, Japan
,
Gloria Kayani
9  Thrombosis Research Institute, London, UK
,
Lorenzo Mantovani
10  University of Milano-Bicocca, Milan, Italy
,
Paolo Prandoni
11  University of Padua, Padua, Italy
,
Sebastian Schellong
12  Municipal Hospital Friedrichstadt, Dresden, Germany
,
Alexander G. G. Turpie
13  McMaster University, Hamilton, Canada
,
Ajay K. Kakkar
9  Thrombosis Research Institute, London, UK
14  University College London, London, UK
› Author Affiliations
Financial support: The GARFIELD-VTE registry is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer Pharma AG (Berlin, Germany).
Further Information

Publication History

Received: 27 April 2016

Accepted after minor revision: 23 August 2016

Publication Date:
09 March 2018 (online)

Summary

Venous thromboembolism (VTE) is a common disorder associated with significant rates of morbidity and mortality. VTE management aims to reduce mortality, the risks of recurrence, and long-term complications. VTE treatment is evolving with the introduction of non-vitamin K antagonist anticoagulants (NOACs). The Global Anticoagulant Registry in the FIELD – Venous Thromboembolism (GARFIELD-VTE) is a prospective, multicentre, observational study that will enrol 10,000 patients treated for acute VTE from ∼500 sites in 28 countries. Identified sites reflect the diversity of care settings, including hospital and outpatient settings. Patients will be managed according to local practices and followed for at least three years. The primary objective is to determine the extent to which VTE treatment varies in the real-world setting and to assess the impact of such variability on clinical and economic outcomes. Evolving patterns of care will be captured using two sequential cohorts. The GARFIELD-VTE registry will provide insights into the evolving global treatment patterns for VTE, both deep-vein thrombosis and pulmonary embolism. By enrolling patients from diverse care settings, the registry will provide information on adherence to national and international guidelines, identify good practice as well as treatment deficiencies, and relate patient outcomes to clinical management. The incidence of death, recurrent VTE, bleeding, post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension will be documented. By capturing information during and after anticoagulation treatment, the registry will not only define aspects of the natural history of VTE, but also its economic and societal impact at a regional and global level.